Granules India enters the high growing peptide segment

Hyderabad-based Granules India has signed an agreement to acquire Senn Chemicals AG, a Swiss-based CDMO specializing in peptides, for CHF 20 million (approx. Rs 192 crore).

Senn develops and manufactures peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025.

This acquisition strengthens Granules India’s presence in peptide-based therapeutics and CDMO segments, a company statement said.

The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics, it added.

Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities.

Stay informed with the latest business news, updates on bank holidays and public holidays.

Unlock Investment Potential: Enroll in ET's Stock Valuation Workshop - Batch 3. Secure Your Spot Now!